[1] |
Klinger, F.; Geier, P.; Dorostkar, M.M.; Chandaka, G.K.; Yousuf, A.; Salzer, I.; Kubista, H.; Boehm, S. Concomitant facilitation of GABAA receptors and KV7 channels by the non-opioid analgesic flupirtine. Br. J. Pharmacol. 2012, 166, 1631–1642.
|
[2] |
Kornhuber, J.; Bleich, S.; Wiltfang, J.; Maler, M.; Parsons, C.G. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. J. Neural. Transm. 1999, 106, 857–867.
|
[3] |
Raffa, R.B.; Pergolizzi Jr, J.V. The evolving understanding of the analgesic mechanism of action of flupirtine. J. Clin. Pharm. Ther. 2012, 37, 4–6.
|
[4] |
Friedel, H.A.; Fitton, A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs. 1993, 45, 548–569.
|
[5] |
Harish, S.; Bhuvana, K.; Bengalorkar, G.M.; Kumar, T. Flupirtine: Clinical pharmacology. J. Anaesthesiol. Clin. Pharmacol. 2012, 28, 172–177.
|
[6] |
Devulder, J. Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs. 2010, 24, 867–881.
|
[7] |
Überall, M.A.; Mueller-Schwefe, G.H.H.; Terhaag, B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr. Med. Res. Opin. 2012, 28, 1617–1634.
|
[8] |
Otto, M.; Cepek, L.; Ratzka, P.; Doehlinger, S.; Boekhoff, I.; Wiltfang, J.; Irle, E.; Pergande, G.; Ellers-Lenz, B.; Windl, O.; Kretzschmar, H.A.; Poser, S.; Prange, H. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology. 2004, 62, 714–718.
|
[9] |
Sättler, M.B.; Williams, S.K.; Neusch, C.; Otto, M.; Pehlke, J.R.; Bähr, M.; Diem, R. Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis. Am. J. Pathol. 2008, 173, 1496–1507.
|
[10] |
Sampath, D.; Shmueli, D.; White, A.M.; Raol, Y.H. Flupirtine effectively prevents development of acute neonatal seizures in an animal model of global hypoxia. Neurosci. Lett. 2015, 607, 46–51.
|
[11] |
Sampath, D.; Valdez, R.; White, A.M.; Raol, Y.H. Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy. Neuropharmacology. 2017, 123, 126–135.
|
[12] |
Abrams, S.M.; Baker, L.R.; Crome, P.; White, A.S.; Johnston, A.; Ankier, S.I.; Warrington, S.J.; Turner, P.; Niebch, G. Pharmacokinetics of flupirtine in elderly volunteers and in patients with moderate renal impairment. Postgrad. Med. J. 1988, 64, 361–363.
|
[13] |
Blackburn-Munro, G.; Dalby-Brown, W.; Mirza, N.R.; Mikkelsen, J.D.; Blackburn-Munro, R.E. Retigabine: chemical synthesis to clinical application. CNS Drug Rev. 2005, 11, 1–20.
|
[14] |
Kandasamy, K.; Gowdra, V.; Nammalvar, H.; Govindarajan, A. Bioanalytical method development, validation and quantification of flupirtine maleate in rat plasma by liquid chromatography-tandem mass spectrometry. Arzneimittelforschung. 2012, 61, 693–699.
|
[15] |
Chen, X.Y.; Zhong, D.F.; Xu, H.Y.; Schug, B.; Blume, H. Simultaneous determination of flupirtine and its major active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 2001, 755, 195–202.
|
[16] |
Scheuch, E.; Methling, K.; Bednarski, P.J.; Oswald, S.; Siegmund, W. Quantitative LC-MS/MS determination of flupirtine, its N-acetylated and two mercapturic acid derivatives in man. J. Pharm. Biomed. Anal. 2015, 102, 377–385.
|
[17] |
Siegmund, W.; Modess, C.; Scheuch, E.; Methling, K.; Keiser, M.; Nassif, A.; Rosskopf, D.; Bednarski, P.J.; Borlak, J.; Terhaag, B. Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1. Br. J. Clin. Pharmacol. 2015, 79, 501–513.
|
[18] |
Liu, X.M.; Wang, L.; Zhang, Y.; Jiang, X.H. Pharmacokinetics and bioequivalence of sustained-release flupirtine maleate tablets in Beagle dogs. Chin. J. Pharm. Anal. 2012, 32, 1731–1735.
|
[19] |
De Vito, V.; Łebkowska-Wieruszewska, B.; Owen, H.; Kowalski, C.J.; Giorgi, M. Pharmacokinetic profiles of the analgesic drug flupirtine in cats. Vet. J. 2014, 202, 309–313.
|
[20] |
Ou-Yang, H.P.; Liu, J.E.; Li, R.H.; Tan, H.Y.; Li, B.; Wang, Y.; Zhang, R.R.; Huang, L. Determination of flupirtine maleate in human plasma by HPLC-FLD and its bioequivalence. Cent. South Pharm. 2013, 11, 30–33.
|
[21] |
Xia, D.Y.; Guo, T.; Liu, L.X.; Tang, Y.B.; Yan, M. Pharmacokinetics of Flupirtine maleate in Chinese Han Nationality Healthy Volunteers. J. Chin. Pharm. 2011, 3, 218–220.
|
[22] |
Liu, Y.F.; Huo, H.; Zhao, Z.; Hu, W.L.; Sun, Y.J.; Tang, Y.B. Bioequivalence study of flupirtine maleate capsules under fasting and fed conditions. Drug Des. Dev. Ther. 2017, 11, 3441–3448.
|
[23] |
FDA. Guidance, Compliance & Regulatory Information (Drugs). 2001. This article can be found online at http://www.fda.gov/Drugs/GuidanceComplianceRegulatory Information/Guidances/default.htm.
|
[24] |
SDA. Chemical agent preparation Bioavailability and biology. Technical guidelines for equivalence research. 2005. This article can be found online at http://www.sda.gov.cn/ WS01/CL1616/83421.html.
|